Cost-of-illness studies of diabetes mellitus: A systematic review

Diabetes Research and Clinical Practice

Volumn 105, Issue 2, 2014, Pages 151-163

  Ng, Charmaine S ^a   Lee, Joyce Y C ^a   Toh, Matthias P H S ^b,c   Ko, Yu ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL HEALTHCARE GROUP   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Cost analysis; Cost of disease; Cost of illness; Diabetes; Economic burden; Healthcare costs

Indexed keywords

COMPLICATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DRUG THERAPY; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL CARE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SYSTEMATIC REVIEW;

COST ANALYSIS; COST OF DISEASE; COST-OF-ILLNESS; DIABETES; ECONOMIC BURDEN; HEALTHCARE COSTS;

COST OF ILLNESS; DIABETES MELLITUS; HEALTH CARE COSTS; HUMANS;

EID: 84906056459     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.03.020     Document Type: Review

References (71)

1. World Health Organisation The global burden of disease: 2004 update 2008, Geneva.
2. IDF Diabetes Atlas Group Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011. Diabetes Res Clin Pract 2013, 100:277-279.
3. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diabetes Res Clin Pract 2013.
4. World Health Organisation, International Diabetes Federation Diabetes action now: an initiative of the World Health Organisation and the International Diabetes Federation 2004, WHO.
5. Amos A.F., McCarty D.J., Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997, 14(Suppl 5):S1-S85.
6. American Diabetes Association Standards of medical care in diabetes-2009. Diabetes Care 2009, 32(Suppl 1):S13-S21.
7. International Diabetes Federation Diabetes atlas 2003, International Diabetes Federation, Brussels, Belgium. 2nd ed.
8. Liu Z., Fu C., Wang W., Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients-a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes 2010, 8(1):62.
9. Ettaro L., Songer T.J., Zhang P., Engelgau M.M. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004, 22(3):149-164.
10. Zhang P., Zhang X., Brown J., Vistisen D., Sicree R., Shaw J., Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293-301.
11. Cooper N.J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford, England) 2000, 39(1):28-33.
12. Druss B., Marcus S., Olfson M., Pincus H. The most expensive medical conditions in America. Health Aff 2002, 21(4):105-111.
13. Fein R. Economics of public health 1958, Basic Books, New York, NY.
14. Mushkin S.J., Collings F. Economic costs of disease and injury. Public Health Rep 1959, 74:795-809.
15. Weisbrod B.A. Economics of public health 1961, University of Pennsylvania Press, Philadelphia, PA.
16. Rice D.P., Cooper B.S. The economic value of human life. Am J Public Health 1967, 57:1954-1966.
17. Cooper B.S., Rice D.P. The economic cost of illness revisited. Social Secur Bull 1976, 39(2):21-36.
18. Rice D.P., Hodgson T.A., Kopstein A.N. The economic costs of illness: a replication and update. Health Care Financ Rev 1985, 7(1):61-80.
19. Hodgson T.A., Meiners M.R. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982, 60(3):429-462.
20. Sam K.G., Philip M.A.K.S. Pharmacoeconomics: cost of illness studies. HYGEIA 2009, 1(1):46-49.
21. Segel J.E. Cost-of-illness studies-a primer. Diabetes 2006, 1-39. RTI-UNC Center of Excellence in Health Promotion Economics.
22. Dagenais S., Caro J., Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J Off J North Am Spine Soc 2008, 8(1):8-20.
23. Zhu T.Y., Tam L.S., Li E.K. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2011, 63(5):751-760.
24. Goetzel R.Z., Hawkins K., Ozminkowski R.J., Wang S. The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003, 45(1):5-14.
25. Rascati K. Measuring and estimating costs. Essentials of pharmacoeconomics 2009, 250. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA.
26. Songer T.J., Ettaro L. Economics of diabetes project panel. Studies on the cost of diabetes 1998, Centers for Disease Control and Prevention, Atlanta, GA.
27. Gonzalez J.C., Walker J.H., Einarson T.R. Cost-of-illness study of type 2 diabetes mellitus in Colombia. Rev Panam Salud Publica 2009, 26(1):55-63.
28. Shaya F.T., Mullins C.D., Wong W. Incidence versus prevalence modeling in pharmacoeconomics. Expert Rev Pharmacoecon Outcomes Res 2002, 2(5):435-442.
29. State Health Policy Gateway (Duke University Center for Health Policy). Cost-of-Illness Measurement United States [cited 2012 10 March]. Available from: http://ushealthpolicygateway.wordpress.com/health-policy-intelligence-sources/f-health-policy-methods/cost-of-illness-measurement/.
30. Koopmanschap M.A., Rutten F.F.H., van Ineveld B.M., van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14(2):171-189.
31. Koopmanschap M.A., van Ineveld B.M. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992, 34(9):1005-1010.
32. OANDA Corporation. Currency converter New York, NY:OANDA Corporation [cited 2012 31 March]. Available from: http://www.oanda.com/currency/converter/.
33. American Diabetes Association Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008, 31(3):596-615.
34. Balu S. Incremental treatment expenditure of diabetes in the United States. Manag Care Interface 2007, 20(4):20-27.
35. Bogner H.R., Miller S.D., de Vries H.F., Chhatre S., Jayadevappa R. Assessment of cost and health resource utilization for elderly patients with heart failure and diabetes mellitus. J Card Fail 2010, 16(6):454-460.
36. Buescher P.A., Whitmire J.T., Pullen-Smith B. Medical care costs for diabetes associated with health disparities among adult Medicaid enrollees in North Carolina. NC Med J 2010, 71(4):319-324.
37. Durden E.D., Alemayehu B., Bouchard J.R., Chu B.C., Aagren M. Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. J Occup Environ Med 2009, 51(12):1460-1465.
38. Fu A.Z., Qiu Y., Radican L., Wells B.J. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care 2009, 32(12):2187-2192.
39. Huang E.S., Basu A., O'Grady M., Capretta J.C. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009, 32(12):2225-2229.
40. Tao B., Pietropaolo M., Atkinson M., Schatz D., Taylor D. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLoS One 2010, 5(7):e11501.
41. Tunceli O., Wade R., Gu T., Bouchard J.R., Aagren M., Luo W. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods. Curr Med Res Opin 2010, 26(8):1827-1834.
42. Kirigia J.M., Sambo H.B., Sambo L.G., Barry S.P. Economic burden of diabetes mellitus in the WHO African region. BMC Int Health Hum Rights 2009, 9(1).
43. Bahia L.R., Araujo D.V., Schaan B.D., Dib S.A., Negrato C.A., Leao M.P., et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health 2011, 14(5 Suppl 1):S137-S140.
44. Pohar S.L., Johnson J.A. Health care utilization and costs in Saskatchewan's registered Indian population with diabetes. BMC Health Serv Res 2007, 7.
45. Abdulkadri A.O., Cunningham-Myrie C., Forrester T. Economic burden of diabetes and hypertension in CARICOM states. Soc Econ Stud 2009, 58(3-4):175-197.
46. Wang W., McGreevey W.P., Fu C., Zhan S., Luan R., Chen W., et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care 2009, 15(9):593-601.
47. Koster I., Huppertz E., Hauner H., Schubert I. Direct costs of diabetes mellitus in Germany-CoDiM 2000-2007. Exp Clin Endocrinol Diabetes 2011, 119(6):377-385.
48. Martin S., Schramm W., Schneider B., Neeser K., Weber C., Lodwig V., et al. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 2007, 115(8):495-501.
49. Athanasakis K., Ollandezos M., Angeli A., Gregoriou A., Geitona M., Kyriopoulos J. Estimating the direct cost of type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Diabet Med 2010, 27(6):679-684.
50. Kumar A., Nagpal J., Bhartia A. Direct cost of ambulatory care of type 2 diabetes in the middle and high income group populace of Delhi: the DEDICOM survey. J Assoc Physicians India 2008, 56:667-674.
51. Tharkar S., Devarajan A., Kumpatla S., Viswanathan V. The socioeconomics of diabetes from a developing country: a population based cost of illness study. Diabetes Res Clin Pract 2010, 89(3):334-340.
52. Esteghamati A., Khalilzadeh O., Anvari M., Meysamie A., Abbasi M., Forouzanfar M., et al. The economic costs of diabetes: a population-based study in Tehran. Iran Diabetol 2009, 52(8):1520-1527.
53. Javanbakht M., Baradaran H.R., Mashayekhi A., Haghdoost A.A., Khamseh M.E., Kharazmi E., et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One 2011, 6:10.
54. Nakamura K., Okamura T., Kanda H., Hayakawa T., Murakami Y., Okayama A., et al. Medical expenditure for diabetic patients: a 10-year follow-up study of National Health Insurance in Shiga. Jpn Public Health 2008, 122(11):1226-1228.
55. van der Linden M.W., Plat A.W., Erkens J.A., Emneus M., Herings R.M. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004. Value Health 2009, 12(6):909-914.
56. Solli O., Jenssen T., Kristiansen I.S. Diabetes: cost of illness in Norway. BMC Endocr Disord 2010, 10.
57. Elrayah-Eliadarous H., Yassin K., Eltom M., Abdelrahman S., Wahlstrom R., Ostenson C.G. Direct costs for care and glycaemic control in patients with type 2 diabetes in Sudan. Exp Clin Endocrinol Diabetes 2010, 118(4):220-225.
58. Bolin K., Gip C., Mörk A.C., Lindgren B. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005-a register-based approach. Diabet Med 2009, 26(9):928-934.
59. Ringborg A., Martinell M., Stålhammar J., Yin D.D., Lindgren P. Resource use and costs of type 2 diabetes in Sweden-estimates from population-based register data. Int J Clin Pract 2008, 62(5):708-716.
60. Wiréhn A.-B., Andersson A., Östgren C.J., Carstensen J. Health economics and care delivery age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis. Diabet Med 2008, 25:732-737.
61. Currie C.J., Gale E.A., Poole C.D. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007*. Diabet Med J Br Diabet Assoc 2010, 27(8):938-948.
62. Zhang Y., Dall T.M., Mann S., Chen Y., Martin J., Moore V., et al. The economic costs of undiagnosed diabetes. Popul Health Manage 2009, 12(2):95-101.
63. Beagley J., Guariguata L., Weil C., Motala A.A. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 2014, 103(2):150-160.
64. Bahadori K., Doyle-Waters M., Marra C., Lynd L., Alasaly K., Swiston J., et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009, 9(1):24.
65. Luppa M., Heinrich S., Angermeyer M.C., Konig H.H., Riedel-Heller S.G. Cost-of-illness studies of depression: a systematic review. J Affect Disord 2007, 98(1-2):29-43.
66. Ruppert A., Steinle T., Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011, 14(1):65-74.
67. Chen E., Looman M., Laouri M., Gallagher M., Van Nuys K., Lakdawalla D., et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010, 26(7):1587-1597.
68. Davis J.C., Robertson M.C., Ashe M.C., Liu-Ambrose T., Khan K.M., Marra C.A. International comparison of cost of falls in older adults living in the community: a systematic review. Osteoporos Int 2010, 21(8):1295-1306.
69. National Institutes of Health Disease-specific estimates of direct and indirect costs of illness and NIH support 1995, National Institute of Health, Bethesda, MD.
70. Bloom B.S., Bruno D.J., Maman D.Y., Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001, 19(2):207-213.
71. Oremus M., Aguilar S.C. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics 2011, 29(2):141-156.